Company / Shareholders' Equity
Caris Life Sciences, Inc. Shareholders' Equity History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$577.3M
FY2025
5-year range
-$2.5B / $577.3M
FY2024-FY2025
Trend
+123.1%
vs FY2024
Sector context
#100 of 160
Health Care
What the data says
At $577M, Caris Life Sciences, Inc.'s shareholders' equity ranks #100 of 160 in the Health Care sector.
Based on SEC 10-K filings.
$577M in FY2025.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#100 of 160 in Health CareTop 62% of 160This company $577.3M Sector average $5.0B
▼
-88.6% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 123.1% year-over-year.
- Ranks #100 out of 160 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $577.3M | +123.1% |
| FY2024 | -$2.5B | - |
| FY2023 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026